Natrium Citrát Grifols (Sodium Citrate)

Sodium citrate binds free calcium ions in the blood, lowering ionized calcium levels. Calcium is essential for several steps in the coagulation cascade; by reducing its availability, citrate interrupts clot formation, allowing blood to remain fluid while it circulates through external circuits or collection devices.

The specific dose of Natrium Citrát Grifols is determined by the prescribing clinician based on the type of procedure, patient weight, renal function, and laboratory monitoring. Healthcare professionals calculate the infusion rate and total amount required to achieve adequate anticoagulation while avoiding hypocalcemia.

Safety data for sodium citrate in pregnant or lactating patients are limited. Because the drug is used primarily in controlled extracorporeal settings, its use during pregnancy or breastfeeding should be evaluated by a qualified physician, weighing potential benefits against any unknown risks to the mother or infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Sodium citrate offers regional anticoagulation by chelating calcium, which can be reversed with calcium infusion after the procedure. Compared with heparin, citrate reduces systemic anticoagulation and bleeding risk, but requires careful monitoring of calcium levels. Choice of anticoagulant depends on patient-specific factors, procedural duration, and institutional protocols.

The product should be stored below 25 °C, protected from direct sunlight, moisture, and extreme temperature fluctuations. Keep the solution in its original, sealed container until use. Follow any additional handling instructions provided by the manufacturer to maintain sterility and potency.

Natrium Citrát Grifols is administered intravenously as part of an extracorporeal circuit. The solution is infused into the blood line before it enters the dialysis or apheresis machine, and the flow rate is adjusted according to the patient’s calcium status and the duration of the procedure.

The most serious risks include severe hypocalcemia, which can cause cardiac arrhythmias, hypotension, and neuromuscular symptoms, as well as metabolic alkalosis. In patients with impaired liver function, citrate accumulation may occur, leading to toxicity. Prompt monitoring and calcium supplementation are essential to mitigate these risks.

Sodium citrate should be avoided in patients with known severe liver disease, uncontrolled hypocalcemia, or those who cannot be closely monitored for electrolyte disturbances. Individuals with a history of severe allergic reactions to citrate or related compounds should also be excluded from its use.